نتائج البحث - "Latiano, T."

1

دورية أكاديمية

Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

المؤلفون: Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, Martinelli, E

المساهمون: Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, Martinelli, E

مصطلحات موضوعية: cetuximab, immunotherapy, metastatic colorectal cancer, rechallenge

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36880426; info:eu-repo/semantics/altIdentifier/wos/WOS:000944145900001; volume:12; issue:8; numberofpages:9; journal:CANCER MEDICINE; https://hdl.handle.net/11568/1169589Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85150336357

الإتاحة: https://doi.org/10.1002/cam4.5699Test
https://hdl.handle.net/11568/1169589Test

View record in BASE

2

دورية أكاديمية

Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)

المساهمون: Ciardiello, D, Chiarazzo, C, Famiglietti, V, Damato, A, Pinto, C, Zampino, M G, Castellano, G, Gervaso, L, Zaniboni, A, Oneda, E, Rapisardi, S, Bordonaro, R, Zichi, C, De Vita, F, Di Maio, M, Parisi, A, Giampieri, R, Berardi, R, Lavacchi, D, Antonuzzo, L, Tamburini, E, Maiorano, B A, Parrella, P, Latiano, T P, Normanno, N, De Stefano, A, Avallone, A, Martini, G, Napolitano, S, Troiani, T, Martinelli, E, Ciardiello, F, Maiello, E

مصطلحات موضوعية: KRASG12C mutation, chemotherapy, first line treatment, mCRC, real-world data

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35994791; info:eu-repo/semantics/altIdentifier/wos/WOS:000861347400014; volume:7; issue:5; firstpage:1; lastpage:7; numberofpages:7; journal:ESMO OPEN; https://hdl.handle.net/2318/1887434Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85136240173; https://www.esmoopen.com/article/S2059-7029Test(22)00195-8/fulltext

الإتاحة: https://doi.org/10.1016/j.esmoop.2022.100567Test
https://hdl.handle.net/2318/1887434Test
https://www.esmoopen.com/article/S2059-7029Test(22)00195-8/fulltext

View record in BASE

3

دورية أكاديمية

O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials

المصدر: Annals of Oncology ; volume 33, page S381-S382 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.04.448Test
https://api.elsevier.com/content/article/PII:S0923753422011383?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422011383?httpAccept=text/plainTest

View record in BASE

4

دورية أكاديمية

Correction to: Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation

المؤلفون: Grandone E., Tiscia G., Pesavento R., De Laurenzo A., Ceccato D., Sartori M. T., Mirabella L., Cinnella G., Mastroianno M., Dalfino L., Colaizzo D., Vettor R., Intrieri M., Ostuni A., Margaglione M., Alboini P. E., Antonioni A., Aucella F., Bochicchio G. B., Carbonelli C., Carella M., Castori M., Centonze A., Ciliberti G., Copetti M., Corritore M., De Cosmo S., D'Aloiso L., D'Errico M. M., de Matthaeis A., Del Gaudio A., Di Giorgio A., Giambra V., Greco A., Florio L., Fontana A., Inchingolo V., Inglese M., Labonia M., La Marca A., Latiano T., Leone M., Maiello E., Mangia A., Marciano C., Massa V., Massafra S., Orciulo G., Palladino N., Perna R., Piscitelli P., Piemontese M., Prencipe M. A., Raggi P., Rodriquenz M. G., Russo R., Sancarlo D., Simeone A., Trischitta V., Zarrelli M., Vaira P., Vergara D., Vescovi A.

المساهمون: Grandone, E., Tiscia, G., Pesavento, R., De Laurenzo, A., Ceccato, D., Sartori, M. T., Mirabella, L., Cinnella, G., Mastroianno, M., Dalfino, L., Colaizzo, D., Vettor, R., Intrieri, M., Ostuni, A., Margaglione, M., Alboini, P. E., Antonioni, A., Aucella, F., Bochicchio, G. B., Carbonelli, C., Carella, M., Castori, M., Centonze, A., Ciliberti, G., Copetti, M., Corritore, M., De Cosmo, S., D'Aloiso, L., D'Errico, M. M., de Matthaeis, A., Del Gaudio, A., Di Giorgio, A., Giambra, V., Greco, A., Florio, L., Fontana, A., Inchingolo, V., Inglese, M., Labonia, M., La Marca, A., Latiano, T., Leone, M., Maiello, E., Mangia, A., Marciano, C., Massa, V., Massafra, S., Orciulo, G., Palladino, N., Perna, R., Piscitelli, P., Piemontese, M., Prencipe, M. A., Raggi, P., Rodriquenz, M. G., Russo, R., Sancarlo, D., Simeone, A., Trischitta, V., Zarrelli, M., Vaira, P., Vergara, D., Vescovi, A.

مصطلحات موضوعية: CSS COVID-19 Group, Covid-19, research groups

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33909262; info:eu-repo/semantics/altIdentifier/wos/WOS:000645162100001; volume:52; issue:3; firstpage:980; lastpage:980; numberofpages:1; journal:JOURNAL OF THROMBOSIS AND THROMBOLYSIS; http://hdl.handle.net/11573/1605462Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105394647

الإتاحة: https://doi.org/10.1007/s11239-021-02460-0Test
http://hdl.handle.net/11573/1605462Test

View record in BASE

5

دورية أكاديمية

Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation

المؤلفون: Grandone E., Tiscia G., Pesavento R., De Laurenzo A., Ceccato D., Sartori M. T., Mirabella L., Cinnella G., Mastroianno M., Dalfino L., Colaizzo D., Vettor R., Intrieri M., Ostuni A., Margaglione M., Alboini P. E., Antonioni A., Aucella F., Bochicchio G. B., Carbonelli C., Carella M., Castori M., Centonze A., Ciliberti G., Copetti M., Corritore M., De Cosmo S., D'Aloiso L., D'Errico M. M., de Matthaeis A., Del Gaudio A., Di Giorgio A., Giambra V., Greco A., Florio L., Fontana A., Inchingolo V., Inglese M., Labonia M., La Marca A., Latiano T., Leone M., Maiello E., Mangia A., Marciano C., Massa V., Massafra S., Orciuli G., Palladino N., Perna R., Piscitelli P., Piemontese M., Prencipe M. A., Raggi P., Rodriquenz M. G., Russo R., Sancarlo D., Simeone A., Trischitta V., Zarrelli M., Vaira P., Vergara D., Vescovi A.

المساهمون: Grandone, E., Tiscia, G., Pesavento, R., De Laurenzo, A., Ceccato, D., Sartori, M. T., Mirabella, L., Cinnella, G., Mastroianno, M., Dalfino, L., Colaizzo, D., Vettor, R., Intrieri, M., Ostuni, A., Margaglione, M., Alboini, P. E., Antonioni, A., Aucella, F., Bochicchio, G. B., Carbonelli, C., Carella, M., Castori, M., Centonze, A., Ciliberti, G., Copetti, M., Corritore, M., De Cosmo, S., D'Aloiso, L., D'Errico, M. M., de Matthaeis, A., Del Gaudio, A., Di Giorgio, A., Giambra, V., Greco, A., Florio, L., Fontana, A., Inchingolo, V., Inglese, M., Labonia, M., La Marca, A., Latiano, T., Leone, M., Maiello, E., Mangia, A., Marciano, C., Massa, V., Massafra, S., Orciuli, G., Palladino, N., Perna, R., Piscitelli, P., Piemontese, M., Prencipe, M. A., Raggi, P., Rodriquenz, M. G., Russo, R., Sancarlo, D., Simeone, A., Trischitta, V., Zarrelli, M., Vaira, P., Vergara, D., Vescovi, A.

مصطلحات موضوعية: COVID-19, low-molecular-weight heparin, mortality, ventilation, aged, aged 80 and over, anticoagulant, clinical decision-making, female, Heparin, low-molecular-weight, hospital mortality, hospitalization, human, male, middle aged, protective factor, risk assessment, risk factor, thromboembolism, time factor, treatment outcome, blood transfusion

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33844150; info:eu-repo/semantics/altIdentifier/wos/WOS:000639512400001; volume:52; issue:3; firstpage:772; lastpage:778; numberofpages:7; journal:JOURNAL OF THROMBOSIS AND THROMBOLYSIS; http://hdl.handle.net/11573/1604745Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85104378528

الإتاحة: https://doi.org/10.1007/s11239-021-02429-zTest
http://hdl.handle.net/11573/1604745Test

View record in BASE

6

دورية أكاديمية

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO

المؤلفون: Rossini D., Lonardi S., Antoniotti C., Santini D., Tomasello G., Ermacora P., Germani M. M., Bergamo F., Ricci V., Caponnetto S., Moretto R., Zaniboni A., Pietrantonio F., Buonadonna A., Ritorto G., Masi G., Latiano T. P., Rapisardi S., Falcone A., Cremolini C.

المساهمون: Rossini, D., Lonardi, S., Antoniotti, C., Santini, D., Tomasello, G., Ermacora, P., Germani, M. M., Bergamo, F., Ricci, V., Caponnetto, S., Moretto, R., Zaniboni, A., Pietrantonio, F., Buonadonna, A., Ritorto, G., Masi, G., Latiano, T. P., Rapisardi, S., Falcone, A., Cremolini, C.

مصطلحات موضوعية: Aged, Antineoplastic Combined Chemotherapy Protocol, Bevacizumab, Camptothecin, Colorectal Neoplasm, Disease Progression, Female, Fluorouracil, Human, Leucovorin, Male, Middle Aged, Neoplasm Recurrence, Local, Organoplatinum Compound, Progression-Free Survival, Salvage Therapy, Treatment Outcome

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33024268; info:eu-repo/semantics/altIdentifier/wos/WOS:000575725800008; volume:124; issue:1; firstpage:183; lastpage:190; numberofpages:8; journal:BRITISH JOURNAL OF CANCER; http://hdl.handle.net/11573/1602242Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85092089076

الإتاحة: https://doi.org/10.1038/s41416-020-01089-9Test
http://hdl.handle.net/11573/1602242Test

View record in BASE

7

دورية أكاديمية

Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy

المؤلفون: Ciardiello D., Famiglietti V., Napolitano S., Esposito L., Normanno N., Avallone A., Latiano T., Maiello E., Pietrantonio F., Cremolini C., Santabarbara G., Pinto C., Troiani T., Martinelli E., Ciardiello F., Martini G.

المساهمون: Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T., Maiello, E., Pietrantonio, F., Cremolini, C., Santabarbara, G., Pinto, C., Troiani, T., Martinelli, E., Ciardiello, F., Martini, G.

مصطلحات موضوعية: Immunotherapy, MCRC, Rechallenge anti‐EGFR, Skin toxicity

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34830870; info:eu-repo/semantics/altIdentifier/wos/WOS:000723622100001; volume:13; issue:22; numberofpages:12; journal:CANCERS; https://hdl.handle.net/11568/1113672Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85118929902; https://www.mdpi.com/2072-6694/13/22/5715Test

الإتاحة: https://doi.org/10.3390/cancers13225715Test
https://hdl.handle.net/11568/1113672Test
https://www.mdpi.com/2072-6694/13/22/5715Test

View record in BASE

8

دورية أكاديمية

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

المؤلفون: Cremolini C., Antoniotti C., Rossini D., Lonardi S., Loupakis F., Pietrantonio F., Bordonaro R., Latiano T. P., Tamburini E., Santini D., Passardi A., Marmorino F., Grande R., Aprile G., Zaniboni A., Murgioni S., Granetto C., Buonadonna A., Moretto R., Corallo S., Cordio S., Antonuzzo L., Tomasello G., Masi G., Ronzoni M., Di Donato S., Carlomagno C., Clavarezza M., Ritorto G., Mambrini A., Roselli M., Cupini S., Mammoliti S., Fenocchio E., Corgna E., Zagonel V., Fontanini G., Ugolini C., Boni L., Falcone A., De Braud F. G. M., Maiello E., Frassineti G. L., Gamucci T., Di Costanzo F., Gianni L., Racca P., Allegrini G., Sobrero A., Aglietta M., Cortesi E., Corsi D. C., Ballestrero A., Bonetti A., Di Clemente F., Ruggeri E., Ciardiello F., Benasso M., Vitello S., Cinieri S., Mosconi S., Silvestris N., Frassoldati A., Bertolini A., Tortora G., Bengala C., Ferrari D., Ardizzoia A., Milandri C., Chiara S., Romano G., Miraglia S., Scaltriti L., Pucci F., Blasi L., Brugnatelli S., Fioretto L., Ribecco A. S., Longarini R., Frisinghelli M., Banzi M.

المساهمون: Cremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., Passardi, A., Marmorino, F., Grande, R., Aprile, G., Zaniboni, A., Murgioni, S., Granetto, C., Buonadonna, A., Moretto, R., Corallo, S., Cordio, S., Antonuzzo, L., Tomasello, G., Masi, G., Ronzoni, M., Di Donato, S., Carlomagno, C., Clavarezza, M., Ritorto, G., Mambrini, A., Roselli, M., Cupini, S., Mammoliti, S., Fenocchio, E., Corgna, E., Zagonel, V., Fontanini, G., Ugolini, C., Boni, L., Falcone, A., De Braud, F. G. M., Maiello, E., Frassineti, G. L., Gamucci, T., Di Costanzo, F., Gianni, L., Racca, P., Allegrini, G., Sobrero, A., Aglietta, M., Cortesi, E., Corsi, D. C., Ballestrero, A., Bonetti, A., Di Clemente, F., Ruggeri, E., Ciardiello, F., Benasso, M., Vitello, S., Cinieri, S., Mosconi, S., Silvestris, N., Frassoldati, A., Bertolini, A., Tortora, G., Bengala, C., Ferrari, D., Ardizzoia, A., Milandri, C., Chiara, S., Romano, G., Miraglia, S., Scaltriti, L., Pucci, F., Blasi, L., Brugnatelli, S., Fioretto, L., Ribecco, A. S., Longarini, R., Frisinghelli, M., Banzi, M.

مصطلحات موضوعية: FOLFOXIRI, bevacizumab, mFOLFOX6, FOLFIRI, metastatic colorectal cancer, TRIBE2 trial, multicentre, open-label, phase 3, randomised controlled, GONO

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32164906; info:eu-repo/semantics/altIdentifier/wos/WOS:000522625000026; volume:21; issue:4; firstpage:497; lastpage:507; numberofpages:11; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/11392/2447390Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85082493423; https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045Test(19)30862-9/fulltext; https://air.unimi.it/retrieve/dfa8b9a3-8968-748b-e053-3a05fe0a3a96/cremoliniTest 2020.pdf

الإتاحة: https://doi.org/10.1016/S1470-2045Test(19)30862-9
http://hdl.handle.net/11392/2447390Test
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045Test(19)30862-9/fulltext
https://air.unimi.it/retrieve/dfa8b9a3-8968-748b-e053-3a05fe0a3a96/cremoliniTest 2020.pdf

View record in BASE

9

دورية أكاديمية

P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy

المصدر: Annals of Oncology ; volume 32, page S167-S168 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.05.254Test
https://api.elsevier.com/content/article/PII:S0923753421014435?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421014435?httpAccept=text/plainTest

View record in BASE

10

دورية أكاديمية

Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development

المؤلفون: Moretto R., Germani M. M., Giordano M., Conca V., Proietti A., Niccoli C., Pietrantonio F., Lonardi S., Tamburini E., Zaniboni A., Passardi A., Latiano T. P., Fanotto V., Di Donato S., Prisciandaro M., Bergamo F., Masi G., Fontanini G., Ugolini C., Cremolini C.

المساهمون: Moretto, R., Germani, M. M., Giordano, M., Conca, V., Proietti, A., Niccoli, C., Pietrantonio, F., Lonardi, S., Tamburini, E., Zaniboni, A., Passardi, A., Latiano, T. P., Fanotto, V., Di Donato, S., Prisciandaro, M., Bergamo, F., Masi, G., Fontanini, G., Ugolini, C., Cremolini, C.

العلاقة: journal:BRITISH JOURNAL OF CANCER; https://hdl.handle.net/11390/1243904Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85147691519

الإتاحة: https://doi.org/10.1038/s41416-023-02180-7Test
https://hdl.handle.net/11390/1243904Test

View record in BASE

تنقيح النتائج